Anti-transthyretin antibodies
AssigneesProthena Biosciences Limited, University Health Network
InventorsYue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Claims36
A vector comprising a nucleic acid encoding a mature heavy chain variable region and a mature light chain variable region operably linked to one or more regulatory sequences to effect expression in a mammalian cell of an antibody comprising the mature heavy chain variable region and mature light chain variable region that binds to human transthyretin, wherein the mature heavy chain variable region comprises three heavy chain CDRs having sequences comprising SEQ ID NOS:67-69, respectively, and the mature light chain variable region comprises three light chain CDRs having sequences comprising SEQ ID NOS:77-79, respectively, except that positions H52 and L26 by Kabat numbering are independently each N or S.
A host cell comprising first and second nucleic acids respectively encoding a mature heavy chain variable region and a mature light chain variable region, each operably linked to one or more regulatory sequences to effect expression of an antibody comprising the mature heavy chain variable region and mature light chain variable region, wherein the mature heavy chain variable region comprises three heavy chain CDRs having sequences comprising SEQ ID NOS:67-69, respectively, and the mature light chain variable region comprises three light chain CDRs having sequences comprising SEQ ID NOS:77-79, respectively, except that positions H52 and L26 by Kabat numbering are independently each N or S.
A method of expressing an antibody in a mammalian cell comprising incorporating first and second nucleic acids respectively encoding a mature heavy chain variable region and a mature light chain variable region, each operably linked to one or more regulatory sequences to effect expression of an antibody comprising the mature heavy chain variable region and mature light chain variable region, wherein the mature heavy chain variable region comprises three heavy chain CDRs having sequences comprising SEQ ID NOS:67-69, respectively, and the mature light chain variable region comprises three light chain CDRs having sequences comprising SEQ ID NOS:77-79, respectively, except that positions H52 and L26 by Kabat numbering are independently each N or S into the genome of a transgenic animal, whereby the antibody is expressed.
Dependencies are inferred from the claim text.